Rich Yang, CEO of Biolinq, describes the San Diego-based company as the “best-kept secret in the biosensing world” that will transform the space, starting with diabetes.
Biolinq is developing a wearable patch that uses tiny microsensors that insert themselves to measure glucose just beneath the skin’s surface and also provides readings directly on the wearable. That sets the technology apart from currently available continuous glucose monitoring (CGMs) systems, including those made by global CGM leaders Abbott and Dexcom, which require an introducer needle to insert a sensor to measure glucose levels in subcutaneous tissue
